CSIMarket
 
Karuna Therapeutics Inc   (KRTX)
Other Ticker:  
 
 
Price: $329.8300 $0.09 0.027%
Day's High: $329.99 Week Perf: 3.33 %
Day's Low: $ 329.75 30 Day Perf: 2.8 %
Volume (M): 1,869 52 Wk High: $ 329.99
Volume (M$): $ 616,287 52 Wk Avg: $222.60
Open: $329.75 52 Wk Low: $158.38



 Market Capitalization (Millions $) 12,431
 Shares Outstanding (Millions) 38
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -396
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 2

Karuna Therapeutics Inc
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for mental health disorders. The company is headquartered in Boston, Massachusetts and was founded in 2009 by Dr. Andrew Miller and Dr. Mark Gurney.

Karunaes mission is to help patients with debilitating psychiatric conditions by discovering and developing medications that target the underlying biological mechanisms of the disease. The company believes that by targeting these mechanisms, they can provide more effective treatments that address the root causes of mental health disorders.

Karuna Therapeuticse lead product candidate is called KarXT, which is a combination of xanomeline and trospium chloride. Xanomeline is a muscarinic acetylcholine receptor agonist that has been shown to improve symptoms of schizophrenia and Alzheimeres disease, while trospium chloride is an approved medication used to treat overactive bladder. The combination of these two drugs has the potential to alleviate schizophrenia symptoms while minimizing side effects such as excessive salivation and gastrointestinal troubles.

Karuna is also developing other therapies for mental health conditions such as depression and anxiety disorders. The companyes preclinical pipeline includes novel compounds that target the glutamatergic system, which is believed to play a role in depression and anxiety.

Karuna Therapeutics has raised over $200 million in funding to date, including a successful initial public offering in 2019. The company has also partnered with various academic and industry partners to advance its research and development efforts.

The management team at Karuna has deep expertise in both drug development and psychiatry/psychology, with several members holding doctorates or other advanced degrees in these areas. This expertise has enabled the company to rapidly advance its drug development programs and secure funding from top-tier investors.

Overall, Karuna Therapeutics is a promising company that is well-positioned to make significant contributions to the treatment of mental health disorders in the future.


   Company Address: 99 High Street Boston 2110 MA
   Company Phone Number: 449-2244   Stock Exchange / Ticker: NASDAQ KRTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Karuna Therapeutics Reports Significant Milestones and Strong Financial Performance in 2023

Published Thu, Feb 22 2024 11:30 AM UTC

Karuna Therapeutics, a leading biopharmaceutical company focused on developing innovative treatments for psychiatric and neurological disorders, has recently released its financial results for the fourth quarter and full year ended December 31, 2023. With groundbreaking achievements, including FDA acceptance of its New Drug Application (NDA) for KarXT in schizophrenia treatm...

Product Service News

Bristol Myers Squibb Set to Revolutionize Neuroscience therapeutics with Karuna Therapeutics Acquisition

Published Fri, Dec 22 2023 12:05 PM UTC

Bristol Myers Squibb Bolsters Neuroscience Portfolio with Karuna Therapeutics AcquisitionPrinceton, N.J. & Boston - In a strategic move to expand its neuroscience portfolio, pharmaceutical giant Bristol Myers Squibb (BMY) has announced its acquisition of Karuna Therapeutics, Inc. (KRTX), a clinical-stage biopharmaceutical company focused on developing novel treatments for ne...

Product Service News

Karuna Therapeutics Takes a Leap Towards Transforming Schizophrenia Treatment with FDA Acceptance of KarXT's New Drug Application

Published Wed, Nov 29 2023 11:30 AM UTC

Karuna Therapeutics, a biopharmaceutical company dedicated to improving the lives of individuals with psychiatric and neurological disorders, has recently announced a significant development in their mission. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KarXT (xanomeline-trospium), a potential treatment for adults suffering from...

Product Service News

Karuna Therapeutics' Breakthrough Phase 1b Trial: Promising Results Show KarXT as a Safe Option for Schizophrenia Patients with No Increase in Blood Pressure

Published Thu, Nov 16 2023 9:01 PM UTC

Karuna Therapeutics Announces Positive Results from Phase 1b Trial of KarXT in Schizophrenia: Findings Yield Encouraging Outcomes on Ambulatory Blood Pressure Monitoring
Boston-based biopharmaceutical company, Karuna Therapeutics, has revealed promising results from its Phase 1b trial evaluating the impact of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressu...

Karuna Therapeutics Inc

Karuna Therapeutics Inc.'s Q3 2023 Financial Results Show Consistent Revenue Growth Compared to Previous Year



Karuna Therapeutics, Inc. has recently released its financial results for the third quarter of 2023, providing insights into the company's performance and future prospects. This article aims to analyze the data and explore how these results might impact the company moving forward.
Financial Results Overview:
During the third quarter of 2023, Karuna Therapeutics achieved a significant milestone by submitting a New Drug Application (NDA) for KarXT, a potential treatment for schizophrenia. This development represents a crucial step forward for both the company and patients living with psychiatric conditions.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com